The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global pneumococcal vaccine market size reached US$ 8.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.6 Billion by 2027, exhibiting a growth rate (CAGR) of 5.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Pneumococcal disease is caused by Streptococcus pneumoniae bacterium that can lead to severe infection of the lungs (pneumonia) and blood (bacteremia) or the lining of the brain and spinal cord (meningitis). The vaccines help protect both children and adults by stimulating the immune system and protecting against the bacterial strains responsible for severe infections. As these vaccines help prevent infection from spreading, reduce fatality rate and eliminate the need for hospitalization, they are widely being used across the globe.
According to the World Health Organization (WHO), children under 2-5 years of age are at a high risk of developing pneumococcal disease. This, in confluence with the escalating number of birth rates and the growing concerns among parents about the health of their children, represents one of the major factors bolstering the market growth. Additionally, the increasing geriatric population is contributing to the market growth. This can also be accredited to the contagiousness of the disease, which can cause severe complications in older adults. Furthermore, the rising number of smokers and individuals living with chronic health conditions is positively influencing the market growth. Moreover, the introduction of the Pneumococcal Conjugate Vaccine (PCV) in infant routine immunization by governing agencies of numerous countries is anticipated to propel the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global pneumococcal vaccine market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on vaccine type, product type, distribution channel and end user.
Breakup by Vaccine Type:
Breakup by Product Type:
Breakup by Distribution Channel:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd and Walvax Biotechnology Co. Ltd.
|Base Year of the Analysis||2021|
|Segment Coverage||Vaccine Type, Product Type, Distribution Channel, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd and Walvax Biotechnology Co. Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global pneumococcal vaccine market was valued at US$ 8.5 Billion in 2021.
We expect the global pneumococcal vaccine market to exhibit a CAGR of 5.4% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic has led to the increasing adoption of pneumococcal vaccine as an immunity booster and a preventive measure against lung injection, especially among the coronavirus-infected patients.
The rising demand for pneumococcal vaccine to help prevent lungs-, blood-, or spinal cord-related infection from spreading, reduce fatality rate, and eliminate the need for hospitalization, is primarily driving the global pneumococcal vaccine market.
Based on the vaccine type, the global pneumococcal vaccine market can be segregated into pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. Currently, pneumococcal conjugate vaccine holds the largest market share.
Based on the product type, the global pneumococcal vaccine market has been divided into Prevnar 13, Synflorix, and Pneumovax 23. Among these, Prevnar 13 currently accounts for the majority of the total market share.
Based on the distribution channel, the global pneumococcal vaccine market can be bifurcated into distribution partner companies, Non-Governmental Organizations (NGO), and government authorities. Currently, Non-Governmental Organizations (NGO) exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global pneumococcal vaccine market include Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd, and Walvax Biotechnology Co. Ltd.
Home Healthcare Market by Product (Therapeutic Products, Testing, Screening, and Monitoring Products, Mobility Care Products), Service (Skilled Nursing, Rehabilitation Therapy, Hospice & Palliative Care, Unskilled Care, Respiratory Therapy, Infusion Therapy, Pregnancy Care), Indication (Cancer, Respiratory Diseases, Movement Disorders, Cardiovascular Diseases & Hypertension, Pregnancy, Wound Care, Diabetes, Hearing Disorders, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at